Research
Hormonal
Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).
Current GLP-1 drugs cause nausea by activating the Area Postrema in the brain, but weight loss is achieved by activating other brainstem areas (NTS). This separation suggests future drugs could be designed to minimize nausea while maintaining weight loss benefits.
GoodQualifiesHIGH confidence
activating GLP-1R-expressing neurons in the AP induces aversion... while in the NTS, this does not seem to be the case... inhibiting GLP-1R-expressing neurons in the AP prevents the aversion caused by exendin-4 and semaglutide, the chronic inhibitory effects of the two GLP-1R agonists on food intake and body weight are preserved
Why this rating
Supported by ablation and inhibition studies in rodent models.
Source
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Mohammed K. Hankir et al. · Pflügers Archiv - European Journal of Physiology · 2024
DOI 10.1007/s00424-024-03047-3
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide, liraglutide) suppress food intake and induce weight loss by targeting distinct neural pathways in the brainstem (NTS, AP, LC, VTA) and hypothalamus, rather than solely relying on peripheral vagal signaling.Good
- Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →